loading page

Regulatory mechanism of miR-223 on platelet reactivity in ischemic stroke patients after clopidogrel treatment
  • +1
  • Wenjie Tian,
  • Xiaoshuang Xia,
  • Yan Sun,
  • Xin Li
Wenjie Tian
Tianjin Medical University Second Hospital
Author Profile
Xiaoshuang Xia
Tianjin Medical University Second Hospital
Author Profile
Yan Sun
Tianjin Medical University Second Hospital
Author Profile
Xin Li
Tianjin Medical University Second Hospital
Author Profile

Abstract

Background: Recent studies have confirmed that microRNA-223 may participate in high-on clopidogrel treatment platelet reactivity. Clopidogrel requires hepatic enzyme metabolic activation to produce its metabolite with pharmacological activity, as a result, there are few researches about platelet reactivity. The aim of the current study is to explore the possible regulatory mechanism between microRNA-223 and platelet reactivity after clopidogrel treatment. Methods: In this study, we established an experimental model of MEG-01 cells treated with clopidogrel and human liver microsomes incubation system, so that the effects of clopidogrel active metabolites on megakaryocytes and platelets can be simulated. The relation of microRNA-223, C/EBP α and P2Y12 was further investigated by both cell experiments and clinical studies. Results: The ratio of platelet P2Y12 expression before and after treatment was significantly higher in Low Responders group (1.14604 vs 0.77097, p=0.031). After treatment at 200 ul/2 ml for 3 and 5 consecutive days, miR-223 expression in MEG-01 cells decreased by 47.3% and 32%, respectively (p < 0.05). P2Y12 mRNA expression was 193.4% higher after 3 consecutive days (p < 0.001), and significantly lower after 5 consecutive days than that in the negative control group (p < 0.05). P2Y12 and C/EBP α protein expression were significantly lower after 5 consecutive days (p < 0.01). Conclusions: A negative feedback loop was carried out by clopidogrel active metabolite to recede its inhibition of P2Y12 signal pathway through P2Y12-PI3K/Akt-C/EBP α-miR-223 pathway, which may be excessively activated and play a role in the occurrence of high-on clopidogrel treatment platelet reactivity.